IRIS
CONTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.626
EU - Europa 894
AS - Asia 194
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 2
Totale 2.721
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.623
UA - Ucraina 201
IT - Italia 171
SE - Svezia 146
IE - Irlanda 109
DE - Germania 104
TR - Turchia 86
DK - Danimarca 72
FI - Finlandia 42
KR - Corea 38
SG - Singapore 37
GB - Regno Unito 26
CN - Cina 22
FR - Francia 13
IN - India 8
BE - Belgio 5
EU - Europa 5
BR - Brasile 2
CA - Canada 2
ID - Indonesia 2
RS - Serbia 2
AT - Austria 1
CH - Svizzera 1
MX - Messico 1
NL - Olanda 1
TW - Taiwan 1
Totale 2.721
Salva come PNG Salva come JPEG
Città #
Chandler 221
Jacksonville 212
Fairfield 176
Dublin 109
Ashburn 102
Wilmington 99
New York 93
Woodbridge 84
Seattle 82
Houston 47
Cambridge 44
Lawrence 43
Princeton 43
San Mateo 43
Boardman 40
Centro 36
Ann Arbor 31
Beijing 22
San Diego 20
Turin 14
Helsinki 9
London 9
Des Moines 8
Marche 8
Pune 8
Redmond 7
Montegiorgio 6
Rome 6
Ancona 5
Brussels 5
Cupra Marittima 5
Norwalk 5
Porto 5
Washington 4
Chiswick 3
Izmir 3
Kilburn 3
Portland 3
Santa Cruz 3
Tolentino 3
Berlin 2
Calgary 2
Colli Del Tronto 2
Hanover 2
Hounslow 2
Los Angeles 2
Modena 2
Montechiarugolo 2
Palermo 2
Rowley 2
San Biagio 2
Segrate 2
Suisio 2
Acton 1
Amsterdam 1
Bolton 1
Broxbourne 1
Cagliari 1
Casalbordino 1
Chicago 1
Cutrofiano 1
Dearborn 1
Falkenstein 1
Fayetteville 1
Florence 1
Frankfurt am Main 1
Holmdel 1
Macerata 1
Milan 1
Morcone 1
Napoli 1
New Taipei 1
Nürnberg 1
Perugia 1
Prescot 1
San Severino Marche 1
Santa Maria a Monte 1
Senigallia 1
Simi Valley 1
Singapore 1
Tappahannock 1
Torino 1
Torre Del Greco 1
Verona 1
Winterthur 1
Totale 1.727
Salva come PNG Salva come JPEG
Nome #
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 98
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 95
Emerging biomarkers in bladder cancer identified by network analysis of transcriptomic data 95
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 93
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 89
Metabolic Alterations in Renal and Prostate Cancer 86
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 84
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 83
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 83
Perivascular epithelioid cell tumor (PEC-ome) of the prostate: ultrasound feature in case report 78
Prostatic fiducial markers implantation by transrectal ultrasound for adaptive image guided radiotherapy in localized cancer: 7-years experience 76
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 76
The route to personalized medicine in bladder cancer: where do we stand? 72
Urinary catheters and biofilm formation 71
Diagnostic-therapeutic pathway for small lesions of the testis 69
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma 68
Present and future of personalized medicine in adult genitourinary tumors 67
NEPHRON-SPARING SURGERY FOR RENAL MASSES >4 CM (CT1B-T2) IN PATIENTS WITH CHRONIC RENAL FAILURE 67
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors 66
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 65
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients 65
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 65
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 64
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 63
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 63
PEC-OME of the prostate: case report 61
Biomarkers for VEGF-targeted therapy in renal cell carcinoma: an UpTo Date 59
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 58
α1-Blockers for the treatment of recurrent urinary tract infections in women with dysfunctional voiding: A prospective randomized study. 57
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 57
Repeated injection of botulinum toxin a in patients with neurogenic bladder: our experience. 53
Efficacy and safety of alfa-1-blockers for the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a prospective study 52
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma 52
Role of STAT3 pathway in genitourinary tumors 52
VEGF and HIF in renal cell carcinogenesis. 51
Sphincter: properties, types and application 50
Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis 49
Recurrent urinary tract infections and dysfunctional voiding 48
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: A systematic review and meta-analysis 46
RESULTS OF NEPHRON-SPARING SURGERY WITHOUT VASCULAR CLAMPING IN PATIENTS WITH CHRONIC RENAL FAILURE 43
Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors 41
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma 38
Survival in Patients with Clear Cell Renal Cell Carcinoma is Predicted by HIF-1α Expression 31
Totale 2.799
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.013
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.013
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20198 0 0 0 0 0 0 0 0 0 0 0 8
2019/2020285 1 1 42 3 48 5 42 2 45 11 22 63
2020/2021713 46 73 87 4 74 34 66 60 77 82 73 37
2021/2022306 33 60 8 9 2 26 5 15 24 28 24 72
2022/2023636 58 94 44 48 48 53 3 40 168 8 48 24
2023/2024377 75 7 28 47 56 131 8 12 3 9 1 0
Totale 2.799